June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Use of Transcutaneous Supraorbital Nerve Stimulation with Cefaly® Device in Patients with Chronic Ocular Pain and Dry Eye Case Series
Author Affiliations & Notes
  • Simran Mangwani Mordani
    Universidad Anáhuac Mexico, Mexico City, CDMX, Mexico
  • Anat Galor
    Bascom Palmer Eye Institute, Florida, United States
    Miami Veterans Administration Hospital, Florida, United States
  • Raquel Goldhardt
    Bascom Palmer Eye Institute, Florida, United States
    Miami Veterans Administration Hospital, Florida, United States
  • Footnotes
    Commercial Relationships   Simran Mangwani Mordani, None; Anat Galor, None; Raquel Goldhardt, None
  • Footnotes
    Support  Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, R01EY026174, NIH Center Core Grant P30EY014801 and Research to Prevent Blindness Unrestricted Grant
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 101. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simran Mangwani Mordani, Anat Galor, Raquel Goldhardt; Use of Transcutaneous Supraorbital Nerve Stimulation with Cefaly® Device in Patients with Chronic Ocular Pain and Dry Eye Case Series. Invest. Ophthalmol. Vis. Sci. 2020;61(7):101.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry eye is a complex multifactorial disease with an increasing prevalence worldwide. Several conventional therapies targeting ocular surface have been used including artificial tears, autologous serum tears and anti-inflammatory drops, yet some patients do not benefit from these. Individuals with chronic ocular pain, wind and light allodynia are suggestive of neuropathic pathway involvement. This study describes the possibility of integrating Cefaly® into the daily routine of patients with dry eye and chronic ocular pain.

Methods : During September 2019, 20-minute Cefaly® Device trials were performed at the Miami Veterans Administration Hospital. Three individuals were identified as candidates for home use Cefaly® due to suspected neuropathic pain and dry eye. Questions regarding ocular pain intensity, dryness, burning sensation, sensitivity to wind and light were asked before and after the Cefaly® trial. The same questions were asked during monthly follow up with a phone interview for a total of two months. Results were reported per patient using a scale ranging from 0-10,” 0” indicating no pain and “10” indicating the most severe pain imaginable.

Results : All three patients were male within the age range of 34-85 years. All patients reported using Cefaly® three times a week for the prescribed 20 minute session. At two months, 2 of three patients reported subjective reduction in pain (8 to 7 and 6 to 3), burning sensation (6 to 3 and 3 to 0) and sensitivity to light (6 to 3 and 7 to 6) but no change in wind sensitivity and ocular dryness. One patient did not report any symptom relief during the two-month follow up. No adverse reactions were reported.

Conclusions : Our data suggest that Cefaly® can be integrated by individuals as adjunctive therapy for dry eye and chronic ocular pain

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×